Buchumschlag

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Carolin Zitzmann, Ruy M. Ribeiro, Aurélien Marc, Xiao‐Jian Zhou, Alan S. Perelson
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
von: Alan Faraj, et al.
Veröffentlicht: (2024)

Navigating the Challenges of Cyclosporine as an Alternative to Rifampicin as an OATP1B Index Inhibitor
von: Manthena V. S. Varma, et al.
Veröffentlicht: (2025)

Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo‐controlled Trial in Constipation
von: Abdulsalam Aliyu, et al.
Veröffentlicht: (2024)

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis
von: Antonio Tursi, et al.
Veröffentlicht: (2026)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
von: Huy X. Ngo, et al.
Veröffentlicht: (2024)

A Consideration of Exploratory Approaches to Comedications Associated With Immune‐Related Adverse Events during Immune Checkpoint Inhibitor Therapy
von: Yoshihiro Noguchi, et al.
Veröffentlicht: (2025)

Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis
von: Hongmei Duan, et al.
Veröffentlicht: (2025)

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data
von: Maria J. Alfonso Arvez, et al.
Veröffentlicht: (2025)

Ocular Complications of SGLT ‐2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in T2DM Treatments: A Retrospective Real‐World Cohort Study
von: Lee‐Yuan Lin, et al.
Veröffentlicht: (2025)

Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase‐4 Inhibitors and Serious Bleeding Events
von: Thanh Phuong Pham Nguyen, et al.
Veröffentlicht: (2024)

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor
von: Sharif I. Soleman, et al.
Veröffentlicht: (2024)

Insights Into Aldosterone Regulation Through Pharmacokinetic–Pharmacodynamic Modeling of an Aldosterone Synthase Inhibitor
von: Javiera Cortés‐Ríos, et al.
Veröffentlicht: (2025)

Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation
von: Shin‐Yi Lin, et al.
Veröffentlicht: (2025)

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing
von: Ashley N. Springer, et al.
Veröffentlicht: (2025)

BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase
von: Aurélie Cabannes‐Hamy, et al.
Veröffentlicht: (2025)

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis
von: Fan Huang, et al.
Veröffentlicht: (2024)

Response to Letters Regarding “Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors”
von: Léonard Laurent, et al.
Veröffentlicht: (2025)

Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form
von: Vivek Purohit, et al.
Veröffentlicht: (2024)

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme
von: Chin Hang Yiu, et al.
Veröffentlicht: (2026)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
von: Jatinder Kaur Mukker, et al.
Veröffentlicht: (2025)

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems
von: Janne T. Backman
Veröffentlicht: (2025)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
von: Natalia Sauer, et al.
Veröffentlicht: (2026)

Moving the Needle for Oncology Dose Optimization: A Call for Action
von: Karthik Venkatakrishnan, et al.
Veröffentlicht: (2024)

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
von: Tania Payo‐Serafín, et al.
Veröffentlicht: (2024)

A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants
von: Xuewen Ma, et al.
Veröffentlicht: (2024)

Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review
von: Patricia Y. Chu, et al.
Veröffentlicht: (2024)

Prenatal and Early Childhood Exposure to Antibiotics or Gastric Acid Inhibitors and Increased Risk of Epilepsy: A Nationwide Population‐Based Study
von: Unnur Gudnadottir, et al.
Veröffentlicht: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
von: Titia Q. Ruijs, et al.
Veröffentlicht: (2024)

From Global Impact to Pharmacoequity: A Call to Action for Clinical Pharmacology
von: Karen Rowland Yeo, et al.
Veröffentlicht: (2026)

Quantitative Systems Toxicology Predicts Ivacaftor‐Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity
von: Alan Shi, et al.
Veröffentlicht: (2025)

Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
von: Teng‐Li Lin, et al.
Veröffentlicht: (2026)

Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement
von: Irina Kareva, et al.
Veröffentlicht: (2025)

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
von: Kenichi Umehara, et al.
Veröffentlicht: (2024)

Use ofCYP2D6Inhibitors withCYP2D6Opioids: Association with Emergency Department Visits for Pain
von: Noor Ahmed Nahid, et al.
Veröffentlicht: (2024)

The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression
von: Gia Han Le, et al.
Veröffentlicht: (2026)

Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A ( LY3509754 ): A Phase I Randomized Placebo‐Controlled Study
von: Amita Datta‐Mannan, et al.
Veröffentlicht: (2024)

Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium–Glucose Cotransporter 2 Inhibitors vs. Non‐Users
von: Hsin‐Fu Lee, et al.
Veröffentlicht: (2024)

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity
von: Patrick O. Hanafin, et al.
Veröffentlicht: (2025)

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL‐1: Clinical Pharmacology Results
von: Jue Gong, et al.
Veröffentlicht: (2025)

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial
von: Dave Singh, et al.
Veröffentlicht: (2025)